Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Biofrontera ( (DE:B8FK) ) has issued an announcement.
Biofrontera AG announced that Biofrontera Inc. is facing payment difficulties, impacting the financial outlook for 2025. Despite an agreement to settle a two million Euro debt, uncertainties remain about Biofrontera Inc.’s ability to fulfill its obligations, potentially affecting Biofrontera AG’s operations and financial health. The situation has led to the withdrawal of previous financial forecasts, with the future viability of Biofrontera Inc. hinging on its ability to secure additional capital or alternative financing.
More about Biofrontera
Biofrontera AG is a company operating in the pharmaceutical industry, with subsidiaries Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH, collectively known as Biofrontera Germany. The company is involved in the development and commercialization of dermatological products, and it is listed on regulated markets in Dusseldorf and Frankfurt, as well as free markets in Berlin, Munich, Stuttgart, and Tradegate.
Average Trading Volume: 1,345
Technical Sentiment Signal: Sell
Current Market Cap: €16.04M
See more data about B8FK stock on TipRanks’ Stock Analysis page.